| 000 | 01011 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250515124214.0 | ||
| 264 | 0 | _c20080811 | |
| 008 | 200808s 0 0 eng d | ||
| 022 | _a1744-7666 | ||
| 024 | 7 |
_a10.1517/14656566.9.10.1773 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLitzow, Mark R | |
| 245 | 0 | 0 |
_aArsenic trioxide. _h[electronic resource] |
| 260 |
_bExpert opinion on pharmacotherapy _cJul 2008 |
||
| 300 |
_a1773-85 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aArsenic Trioxide |
| 650 | 0 | 4 |
_aArsenicals _xadverse effects |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Promyelocytic, Acute _xdrug therapy |
| 650 | 0 | 4 |
_aOxides _xadverse effects |
| 650 | 0 | 4 | _aRecurrence |
| 773 | 0 |
_tExpert opinion on pharmacotherapy _gvol. 9 _gno. 10 _gp. 1773-85 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14656566.9.10.1773 _zAvailable from publisher's website |
| 999 |
_c18054788 _d18054788 |
||